Meryl Waldman

Credentials: · ·

History

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
Journal of Clinical Investigation · 2018 · 420 citations
Adult minimal-change disease: clinical characteristics, treatment, and outcomes
Clinical Journal of the American Society of Nephrology · 2007 · First of 8 authors · Corresponding · 317 citations
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis
Review · American Journal of Kidney Diseases · 2013 · Last of 9 authors · 173 citations

Studies of Immunologically-Mediated Kidney Diseases
National Institute of Diabetes and Digestive and Kidney Diseases · ZIA
Contact PI · $1.2M · National Institute of Diabetes and Digestive and Kidney Diseases
Treatment Trials- Rituximab Plus Cyclosporine for MN and Belimumab Plus Rituximab for MN (REBOOT)
National Institute of Diabetes and Digestive and Kidney Diseases · ZIA
Contact PI · $491K · National Institute of Diabetes and Digestive and Kidney Diseases
Apellis RWD (Retro) Protocol
National Institute of Diabetes and Digestive and Kidney Diseases · ZIA
Contact PI · $7.5K · National Institute of Diabetes and Digestive and Kidney Diseases

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Principal investigator · Recruiting · Phase 2
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2010–2027
Immune System Related Kidney Disease
Principal investigator · Recruiting
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1992
Determination of Kidney Function
Principal investigator · Terminated
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
1989–2020
Belimumab With Rituximab for Primary Membranous Nephropathy
Site PI · Recruiting · Phase 2
National Institute of Allergy and Infectious Diseases (NIAID)
2020–2030